Pathfinder Cell Therapy, Inc. (PFND)

USD 0.0

(0.0%)

Market Cap (In USD)

66.71 Thousand

Revenue (In USD)

-

Net Income (In USD)

-1.66 Million

Avg. Volume

324.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-6-1.0E-4
PE
-
EPS
-
Beta Value
-24.332
ISIN
US70319A1060
CUSIP
-
CIK
-
Shares
667161000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Richard L. Franklin
Employee Count
-
Website
https://www.pathfindercelltherapy.com
Ipo Date
2000-01-03
Details
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.